These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. MHC class I antigens, immune surveillance, and tumor immune escape. Garcia-Lora A; Algarra I; Garrido F J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644 [TBL] [Abstract][Full Text] [Related]
11. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines. Mocellin S; Nitti D Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549 [TBL] [Abstract][Full Text] [Related]
12. [Cancer immunotherapy: immunologic bases, reality and hopes]. Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939 [TBL] [Abstract][Full Text] [Related]
14. Vaccine therapy for cancer: fact or fiction? Odunsi K; Lele S; Savalgi R Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673 [TBL] [Abstract][Full Text] [Related]
15. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
16. Current developments in cancer vaccines and cellular immunotherapy. Ribas A; Butterfield LH; Glaspy JA; Economou JS J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342 [TBL] [Abstract][Full Text] [Related]
17. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Jinushi M; Hodi FS; Dranoff G Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009 [TBL] [Abstract][Full Text] [Related]
18. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Chouaib S; Meslin F; Thiery J; Mami-Chouaib F Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109 [TBL] [Abstract][Full Text] [Related]